Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 03 Nov, 18:33 UTC

Following 12 weeks of treatment, Recursion said, 87% of patients (13 of 15) had a reduction in total polyp burden, with a 47% median reduction. Approximately one in three patients achieved reductions of ≥65%. The post Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II…